Krystal Biotech Inc (KRYS) - Total Liabilities
Based on the latest financial reports, Krystal Biotech Inc (KRYS) has total liabilities worth $141.52 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Krystal Biotech Inc (KRYS) long-term investment share to see how much of total assets are deployed in long-term investments.
Krystal Biotech Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Krystal Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Krystal Biotech Inc assets under control.
Krystal Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Krystal Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mazagon Dock Shipbuilders Limited
NSE:MAZDOCK
|
India | Rs174.74 Billion |
|
Donaldson Company Inc
NYSE:DCI
|
USA | $1.39 Billion |
|
AvalonBay Communities Inc
NYSE:AVB
|
USA | $10.07 Billion |
|
Jinduicheng Molybdenum Co Ltd
SHG:601958
|
China | CN¥2.85 Billion |
|
Getlink SE
PA:GET
|
France | €6.35 Billion |
|
Advanced Drainage Systems Inc
NYSE:WMS
|
USA | $2.55 Billion |
|
Jyske Bank A/S
CO:JYSK
|
Denmark | Dkr708.46 Billion |
|
RYOHIN UNSP.ADR/1
F:3RKU
|
Germany | €247.81 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Krystal Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Krystal Biotech Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Krystal Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Krystal Biotech Inc (2016–2025)
The table below shows the annual total liabilities of Krystal Biotech Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $114.23 Million | +4.36% |
| 2024-12-31 | $109.46 Million | +175.62% |
| 2023-12-31 | $39.71 Million | +9.65% |
| 2022-12-31 | $36.22 Million | +10.70% |
| 2021-12-31 | $32.72 Million | +74.41% |
| 2020-12-31 | $18.76 Million | +207.09% |
| 2019-12-31 | $6.11 Million | +111.38% |
| 2018-12-31 | $2.89 Million | +351.56% |
| 2017-12-31 | $640.00K | -66.19% |
| 2016-12-31 | $1.89 Million | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more